title: [Antazoline/tetryzoline eyedrops in comparison with levocabastine eyedrops in acute allergic conjunctivitis].
abstract: BACKGROUND
  Allergic conjunctivitis is one of the most frequent allergic diseases of the anterior eye segment.
  
  
  METHODS
  This multicentre, clinical trial was an investigation to compare the antiallergic efficacy, local tolerance and safety of Antazolin/Tetryzolin eye drops and Levocabastine eye drops. 69 patients were treated over a 2 weeks course of therapy. The subjective and objective ocular symptoms were documented over the treatment period.
  
  
  RESULTS
  Both eye drops reduced subjective and objective ocular symptoms effective. The difference between the treatments (p = 0.0395) was the faster onset of action of Antazolin/Tetryzolin 30 minutes after administration of the first drop of trial medication.
  
  
  CONCLUSIONS
  A fast and effective onset of action is of high clinical relevance. Therefore the benefits of using Antazolin/Tetryzolin eye drops was clearly outweigh.
authors.affiliation: Augenklinik Rechts der Isar der Technischen Universität München.
authors.forename: R
authors.initials: R
authors.lastname: Wertheimer
authors.forename: G
authors.initials: G
authors.lastname: Blessmann
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000865:Antazoline / Q000008:administration & dosage* / Q000009:adverse effects; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000008:administration & dosage* / Q000009:adverse effects; D009883:Ophthalmic Solutions; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D018926:Anti-Allergic Agents; D004338:Drug Combinations; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D014663:Nasal Decongestants; D009883:Ophthalmic Solutions; D010880:Piperidines; D000865:Antazoline; C047340:levocabastine; C005810:tetrahydrozoline